Compugen’s Unigen AI/ML platform drives the discovery of potentially novel checkpoints. Find out what nudges me to rate CGEN ...

Forlong Biotechology inks agreement with Shanghai Henlius Biotech to develop cancer immunotherapy: Shanghai Friday, October 24, 2025, 17:00 Hrs [IST] Forlong Biotechnology, a clin ...

Icotrokinra demonstrated clinically meaningful outcomes at Week 28 in the Phase 2b ANTHEM-UC study in ulcerative colitis, with 31.7% of patients achieving clinical remission and 38.1% showing ...

The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that it has entered into a ...

Deutsche Börse AG ( OTCPK:DBOEF) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT ...

For Satyajit Banerjee of GrownUpTales, finance is storytelling, not jargon. The finfluencer believes new creators should ...

Takeda to Receive Rights to Two Next-Generation Late-Stage Investigational Medicines, Worldwide Outside of Greater China, and an Exclusive Option to License Global Rights to an Early-Stage ...

NAPLES, FL / ACCESS Newswire / October 27, 2025 / "STEMTECH CORPORATION", the global leader and pioneer in stem cell nutrition and Innoventure Dynamic LLC of India announced on October 23, 2025, ...

Detailed price information for Lantern Pharma Inc (LTRN-Q) from The Globe and Mail including charting and trades.

Takeda will pay $1.2 billion upfront, including a $100 million equity investment, for rights to two programs and the option to license a third candidate.

Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across ...